PROF / Profound Medical Corp. - SEC-Einreichungen, Jahresbericht, Proxy Statement

PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 13, 2026 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 2, 2026 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 13, 2026 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 2, 2026 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 PROFOUND MEDICAL COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring

EXHIBIT 99.1 Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring TORONTO, May 14, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 PROFOUND MEDICAL COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

As filed with the Securities and Exchange Commission on May 12, 2026

As filed with the Securities and Exchange Commission on May 12, 2026 Registration No.

Security Type

Calculation of Filing Fee Tables S-3 Profound Medical Corp. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Init

Profound Medical Reports Strong First Quarter 2026 Financial Results – Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULS

EXHIBIT 99.1 Profound Medical Reports Strong First Quarter 2026 Financial Results – Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues full-year 2026 revenue guidance – – Announces Humana is now covering the TULSA Procedure™ – TORONTO, May 07, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PROFOUND MEDICAL CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2026 PROFOUND MEDICAL C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow TORONTO, April 16, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, will announc

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

EXHIBIT 99.1 Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 14, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 PROFOUND MEDICAL C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting

EXHIBIT 99.1 Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting TORONTO, April 01, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 PROFOUND MEDICAL CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone

EXHIBIT 99.1 Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone TORONTO, March 27, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 PROFOUND MEDICAL C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence – First multicenter, randomized controlled trial dire

EXHIBIT 99.1 CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence – First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TUL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2026 PROFOUND MEDICAL C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 PROFOUND MEDICAL CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 PROFOUND MEDICAL CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

EXHIBIT 99.1 Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24 TORONTO, March 09, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-f

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing of our Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report on Form 10-K”), Profound Medical Corp. (“Profound,” the “Company,” “we,” “us” and “our”) has one class of securities registered under Section 12 of the Securities Exchange A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39

Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

EXHIBIT 99.1 Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results TORONTO, March 05, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year e

Amended and restated LONG TERM INCENTIVE PLAN Effective as of May 20, 2020 and Amended and Restated as of April 3, 2023

Exhibit 10.5 Amended and restated LONG TERM INCENTIVE PLAN Effective as of May 20, 2020 and Amended and Restated as of April 3, 2023 PROFOUND MEDICAL CORPORATION LONG TERM INCENTIVE PLAN The purpose of this Plan is to advance the interests of the Company by: (i) providing Eligible Persons with additional incentives; (ii) rewarding performance by Participants; (iii) increasing the proprietary inter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 PROFOUND MEDICAL CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quart

Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease

EXHIBIT 99.1 Profound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is pleased to announce that it has received the 2025/2026 Mount Logan Awar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2026 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions

EXHIBIT 99.1 PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical dev

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical Announces Upcoming Investor Events

EXHIBIT 99.1 Profound Medical Announces Upcoming Investor Events TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce its participation in the following inves

Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO® Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospita

EXHIBIT 99.1 Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO® Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked No. 6 nationally for Urology by US News & World Report® for 2025-26 TORONTO, Jan. 15, 2026 (GLOBE NEWSWIRE) - Profound Medica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Surpasses 2025 TULSA-PRO® Installed Base Goal Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems

EXHIBIT 99.1 Profound Surpasses 2025 TULSA-PRO® Installed Base Goal Company’s year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

EXHIBIT 99.1 Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care TORONTO, Jan. 06, 2026 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and market

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2026 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2026 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (

PROFOUND MEDICAL CORP. SUBSCRIPTION AGREEMENT FOR COMMON SHARES (for use by Canadian and Offshore Subscribers)

Exhibit 10.1 PROFOUND MEDICAL CORP. SUBSCRIPTION AGREEMENT FOR COMMON SHARES (for use by Canadian and Offshore Subscribers) TO:      PROFOUND MEDICAL CORP. (the “Corporation”) The undersigned (hereinafter referred to as the “Subscriber”) hereby irrevocably subscribes for and agrees to purchase from the Corporation the number of common shares in the capital of the Corporation (each a “Common Share”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical Corp. Announces Closing of Private Placement

Exhibit 99.1 Profound Medical Corp. Announces Closing of Private Placement TORONTO, December 30, 2025 – Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”). Pursuant to the Offering, the Company issued an aggregate of 921,428 common

PROFOUND MEDICAL CORP. 5,142,870 Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-291516 Prospectus Supplement (To prospectus dated December 4, 2025) PROFOUND MEDICAL CORP. 5,142,870 Common Shares We are offering 5,142,870 common shares directly to institutional investors pursuant to this prospectus supplement and the accompanying prospectus. Each common share will be sold in this offering at a purchase price equal to $7.00.

PLACEMENT AGENCY AGREEMENT

Exhibit 1.1 PLACEMENT AGENCY AGREEMENT December 19, 2025 Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC 7 World Trade Center, 46th Floor New York, NY 10007 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Profound Medical Corp., an Ontario corporation (the “Company”), hereby agrees to sell up to an aggregate of $36,000,000

Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement

Exhibit 99.1 Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, December 19, 2025 – Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today annou

SHARE PURCHASE AGREEMENT

Exhibit 10.1 SHARE PURCHASE AGREEMENT This Share Purchase Agreement (this “Agreement”) is dated as of December 19, 2025, between Profound Medical Corp., an Ontario corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5

Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5 December 2, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Profound Medical Corp. Registration Statement on Form S-3 Filed November 13, 2025 File No. 333-291516 Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 o

Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potenti

EXHIBIT 99.1 Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Security Type

Calculation of Filing Fee Tables S-3 Profound Medical Corp. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Init

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.

PROFOUND MEDICAL CORP. as Issuer, as U.S. Trustee as Canadian Trustee Dated as of [__________] Table of Contents

Exhibit 4.4 PROFOUND MEDICAL CORP. as Issuer, [] as U.S. Trustee and [] as Canadian Trustee Indenture Dated as of [] Table of Contents Page Article One DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01. Definitions. 1 Section 1.02. Compliance Certificates and Opinions. 12 Section 1.03. Form of Documents Delivered to Trustees. 12 Section 1.04. Acts of Holders. 13 Section 1.05.

As filed with the Securities and Exchange Commission on November 13, 2025

As filed with the Securities and Exchange Commission on November 13, 2025 Registration No.

Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

EXHIBIT 99.1 Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tis

EXHIBIT 99.1 Profound Medical Inks Exclusive Distribution Agreement for TULSA-PRO® and Sonalleve® with Al Faisaliah Medical Systems in Saudi Arabia Agreement creates runway for Profound’s incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East All required regulatory approvals to import and sell Profound’s two ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 PROFOUND MEDICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation)

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

EXHIBIT 99.1 Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, incision-free therapies for the ablation of diseased tis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter To release full third quarter 2025 financial results on November 13th; conference call to follow

EXHIBIT 99.1 Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter To release full third quarter 2025 financial results on November 13th; conference call to follow TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable,

Profound Medical Announces Second Quarter 2025 Financial Results

EXHIBIT 99.1 Profound Medical Announces Second Quarter 2025 Financial Results TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PROFOUND MEDICAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.

Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO®

EXHIBIT 99.1 Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO® TORONTO, June 04, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it h

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.

Profound Medical Announces First Quarter 2025 Financial Results

EXHIBIT 99.1 Profound Medical Announces First Quarter 2025 Financial Results TORONTO, May 08, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Comm

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy – First Level 1 study comparing an emerging technology

EXHIBIT 99.1 Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy – First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pa

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

Establishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer • CAPTAIN Level 1 randomized controlled trial, peri - operative data and patient experience • Dr.

Exhibit 99.1 Establishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer • CAPTAIN Level 1 randomized controlled trial, peri - operative data and patient experience • Dr. Ram Pathak’s TULSA experience, outcomes and efficient interventional MRI workflow BPH • Strategy for market introduction of TULSA for BPH

PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 14, 2025 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 4, 2025 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 14, 2025 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 4, 2025 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) i

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C

Form 52 – 109F2 – Certification of Interim Filings – CEO

Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended June 30, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (tog

Form 52 – 109F2 – Certification of Interim Filings – CFO

Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended March 31, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (to

Form 52 – 109F2 – Certification of Interim Filings – CFO

Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended June 30, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (tog

Unaudited Interim Condensed Consolidated Financial Statements

Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying una

Unaudited Interim Condensed Consolidated Financial Statements

Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5

Form 52 – 109F2 – Certification of Interim Filings – CEO

Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended September 30, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5

Management’s Discussion and Analysis

Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principles in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5

Management’s Discussion and Analysis

Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principles in

Form 52 – 109F2 – Certification of Interim Filings – CEO

Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended March 31, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (to

Form 52 – 109F2 – Certification of Interim Filings – CFO

Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended September 30, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A

Unaudited Interim Condensed Consolidated Financial Statements

Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying unau

Management’s Discussion and Analysis

Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principle

Subsidiaries of the Company

Exhibit 21 SUBSIDIARIES OF THE COMPANY Name Subsidiary Jurisdiction Profound Medical Inc. Canada 2753079 Ontario Inc. Canada Profound Medical Oy Finland Profound Medical Technology Services (Beijing) Co., Ltd. China Profound Medical GmbH Germany Profound Medical (U.S.) Inc. United States

Profound Medical Corp. Corporate Disclosure, Confidentiality and Trading in Securities by Directors, Officers, Employees and Consultants Policy

Exhibit 19 Title: CORPORATE DISCLOSURE, CONFIDENTIALITY AND TRADING IN SECURITIES POLICY PAGE 1 of 18 Document Number HR-SP-POLICY019 Revision 3 PROFOUND MEDICAL CORP.

Description of Securities

Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing of our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report on Form 10-K”), Profound Medical Corp. (“Profound,” the “Company,” “we,” “us” and “our”) has one class of securities registered under Section 12 of the Securities Exchange A

Specimen Share Certificate

Exhibit 4.2

Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results TORONTO, March 06, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39

Amended and Restated Technology License Agreement, dated May 16, 2011, by and between the Company and Sunnybrook Health Sciences Centre

Exhibit 10.7 AMENDED AND RESTATED TECHNOLOGY LICENCE AGREEMENT THIS AMENDED AND RESTATED TECHNOLOGY LICENCE AGREEMENT is made as of May 16, 2011 BETWEEN: SUNNYBROOK HEALTH SCIENCES CENTRE, with offices located at 2075 Bayview Avenue in Toronto, Ontario (the “Licensor”) - and- PROFOUND MEDICAL INC., a company governed by the laws of the Province of Ontario (the “Licensee”) RECITALS: A. The Inventor

Amended and Restated Employment Agreement, dated August 20, 2019, as amended, by and between the Company and Mathieu Burtnyk

Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) dated as of August 20, 2019 (the“Effective Date”) BETWEEN: PROFOUND MEDICAL CORP. (the “Company”) AND: MATHIEU BURTNYK (the “Employee”) WHEREAS the Company and the Employee entered into a letter agreement as to employment on June 3, 2011 (the “Original Agreement”); and WHEREAS th

Employment Agreement, dated January 1, 2020, as amended, by and between the Company and Arun Menawat

Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of the 1st day of January, 2020 (the “Effective Date”). BETWEEN: PROFOUND MEDICAL (US) INC. (the “Company”) AND, for the limited purposes of Sections 1.1, 2.3 and 16.1 hereof: PROFOUND MEDICAL CORP. (the “Parent”) AND: ARUN MENAWAT (the “Employee”) WHEREAS Parent, which owns 100% of the equity of

Amended and Restated Employment Agreement, dated August 23, 2019, as amended, by and between the Company and Rashed Dewan

Exhibit 10.3 EMPLOYMENT AGREEMENT THIS AGREEMENT dated as of March 22, 2022, has an effective date of February 1, 2022 (the “Start date”), and signed acceptance of this agreement date of on or before March 23, 2022, the expiry date of this offer of employment. BETWEEN: Profound (the “Employer” or “Company”) AND: Rashed Dewan (the “Employee”) WHEREAS: A. The Employer has offered to employ the Emplo

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co

Siemens Agreement dated January 23, 2019. between the Company and Siemens Healthcare GmbH

Exhibit 10.8 SIEMENS ID Agreement by and between Profound Medical Inc. (- hereinafter referred to as “the Receiver” -) and SIEMENS Healthcare GmbH (- hereinafter referred to as “SIEMENS” -) - the Receiver and SIEMENS hereinafter referred to individually as “PARTY” or collectively as “PARTIES” - on the provision of information regarding SIEMENS’ interface CONFIDENTIAL 2 / 26 Contents Preamble 3 Art

Employment Agreement, dated October 14, 2024, by and between the Company and Tom Tamberrino

Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of the 14th day of October 2024 (the “Effective Date”). BETWEEN: PROFOUND MEDICAL (US) INC. (the “Company”) AND: THOMAS TAMBERRINO (the “Employee”) NOW THEREFORE in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each of the parties, the parties agree as follows:

Amended and Restated Credit Agreement, dated March 3, 2025, between the Company and Canadian Imperial Bank of Commerce

Exhibit 10.9 [***] Certain information has been excluded from this exhibit because it is both not material and the type that the Registrant treats as private or confidential. AMENDED AND RESTATED CREDIT AGREEMENT between PROFOUND MEDICAL INC. as Borrower AND PROFOUND MEDICAL CORP. 2753079 ONTARIO INC. PROFOUND MEDICAL (U.S.) INC. and PROFOUND MEDICAL GMBH as Guarantors AND CANADIAN IMPERIAL BANK O

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues – Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC o

EXHIBIT 99.1 Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues – Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORON

Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EXHIBIT 99.1 Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present

FORM 51-102F3 MATERIAL CHANGE REPORT

Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change December 6, 2024 3. News Release A press release relating to the material change was disseminated via Globe Newswire on December 6, 2024 and was subsequently filed on SEDAR+. 4. Summ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

EXHIBIT 99.1 Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering pric

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR

Exhibit 99.2 Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, ON (December 6, 2024) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwr

PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 10, 2024

TABLE OF CONTENTS  Filed pursuant to General Instruction II.L of Form F-10   File No. 333-280236 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated July 10, 2024 to which it relates, as amended or supplemented, and each document incorporated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

PROFOUND MEDICAL CORP. 4,666,700 Common Shares UNDERWRITING AGREEMENT

Exhibit 99.1 Execution Version PROFOUND MEDICAL CORP. 4,666,700 Common Shares UNDERWRITING AGREEMENT December 6, 2024 RAYMOND JAMES LTD. Lake Street Capital Markets, LLC As representatives of the several underwriters c/o Raymond James Ltd. 40 King St. W., 54th Floor Toronto, Ontario M5H 3Y2 c/o Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700, Minneapolis, MN 55402 United States

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR

EXHIBIT 99.1 Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+

Exhibit 99.3 Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ TORONTO, ON (December 5, 2024) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in

Osler, Hoskin & Harcourt

Exhibit 99.2 Osler, Hoskin & Harcourt llp Box 50, 1 First Canadian Place Toronto, Ontario, Canada M5X 1B8 416.362.2111 main 416.862.6666 facsimile Toronto Montréal Ottawa Calgary New York December 5, 2024 Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5 Dear Sirs/Mesdames: Profound Medical Corp. (the “Issuer”) We refer you to the prospectus supplement dated December

PRELIMINARY PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 10, 2024

TABLE OF CONTENTS  Filed pursuant to General Instruction II.L of Form F-10   File No. 333-280236 A copy of this preliminary prospectus supplement has been filed with the securities regulatory authorities in each of the provinces and territories of Canada but has not yet become final for the purpose of the sale of securities. Information contained in this preliminary prospectus supplement may not b

BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON MINTZ LLP

Exhibit 99.1 200 Bay Street, South Tower Suite 2800 Toronto, ON 647 499 2828 mintz.com December 5, 2024 Profound Medical Corp. 2400 Skymark Avenue, Unit 6 Mississauga, Ontario L4W 5K5, Canada Ladies and Gentlemen: Re: Registration Statement on Form F-10 We hereby consent to the references to our firm name in the prospectus filed as part of this registration statement on Form F-10 of Profound Medic

Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR

EXHIBIT 99.1 Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy – Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurat

EXHIBIT 99.1 Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy – Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meeti

EXHIBIT 99.1 Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s

PROF / Profound Medical Corp. / GAGNON SECURITIES LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

Profound Medical to Participate in the Stifel 2024 Healthcare Conference

EXHIBIT 99.1 Profound Medical to Participate in the Stifel 2024 Healthcare Conference TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an upda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and nine months ended September 30, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of November 7, 2024 should be read in conjunction with the Septemb

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Based on

PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, 2024 $ December 31, 2023 $ Assets Current assets Cash 27,123 26,213 Trade and other receivables (note 3) 7,030 7,288 Inventory (note 4) 6,435 6,989 Prepa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical Announces Third Quarter 2024 Financial Results

EXHIBIT 99.1 Profound Medical Announces Third Quarter 2024 Financial Results TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Based

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level

EXHIBIT 99.1 Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer – Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to mak

EXHIBIT 99.1 Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer – Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA - Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemen

EXHIBIT 99.1 Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA - Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution f

As filed with the Securities and Exchange Commission on September 12, 2024

As filed with the Securities and Exchange Commission on September 12, 2024 Registration No.

Filing Fee Table.

EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Profound Medical Corp.

Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference

EXHIBIT 99.1 Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and six months ended June 30, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of August 8, 2024 should be read in conjunction with the March 31, 2024 unaud

Profound Medical Announces Second Quarter 2024 Financial Results

EXHIBIT 99.1 Profound Medical Announces Second Quarter 2024 Financial Results TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ende

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2024. 2. No misrepresentations: Based on my kn

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2024. 2. No misrepresentations: Based on m

PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) June 30, 2024 $ December 31, 2023 $ Assets Current assets Cash 34,079 26,213 Trade and other receivables (note 3) 7,162 7,288 Inventory (note 4) 6,732 6,989 Prepaid expense

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-390

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princi

PROF / Profound Medical Corp. / Bdc Capital Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Profound Medical Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74319B502 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow TORONTO, July 18, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39032

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principa

As filed with the Securities and Exchange Commission on July 10, 2024.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 10, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X Appointment of Agent For Service of Process And Undertaking

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X Appointment of Agent For Service of Process And Undertaking A. Name of issuer or person filing (the “Filer”): Profound Medical Corp. B. (1) This is (check one): x  an original filing for the Filer ¨   an amended filing for the Filer       (2) Check the following box if you are filing the Form F-X in paper in accordanc

Form of Indenture

Exhibit 7.1 PROFOUND MEDICAL CORP. as Issuer, [] as U.S. Trustee and [] as Canadian Trustee Indenture Dated as of [] Table of Contents Page Article One DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01. Definitions 1 Section 1.02. Compliance Certificates and Opinions 12 Section 1.03. Form of Documents Delivered to Trustees 12 Section 1.04. Acts of Holders 13 Section 1.05. Noti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of p

As filed with the Securities and Exchange Commission on June 14, 2024.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 14, 2024.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables FORM F-10 (Form Type) PROFOUND MEDICAL CORP.

FORM 51-102F3 MATERIAL CHANGE REPORT

Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change January 16, 2024 3. News Release A press release relating to the material change was disseminated via Globe Newswire on January 16, 2024 and was subsequently filed on SEDAR+. 4. Summ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 5, 2024 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 5, 2024 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual general meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) in the capita

Profound Medical Annual General Meeting of Shareholders Voting Results

EXHIBIT 99.1 Profound Medical Annual General Meeting of Shareholders Voting Results TORONTO, May 15, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the “Meeting”). A total of 15,336,388 common shares, representing 62.78% of the common

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal

Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 p

EXHIBIT 99.1 Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader, multi-case clinical studies conducted by wor

Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance

EXHIBIT 99.1 Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance TORONTO, May 09, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fina

PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) March 31, 2024 $ December 31, 2023 $ Assets Current assets Cash 41,180 26,213 Trade and other receivables (note 3) 6,510 7,288 Inventory (note 4) 6,976 6,989 Prepaid expen

PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s)

Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three months ended March 31, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of May 9, 2024 should be read in conjunction with the March 31, 2024 unaudited inte

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on my k

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum — So far this year alone, 25 TULSA-related scientific research presen

EXHIBIT 99.1 Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum — So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip

Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow TORONTO, April 22, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its firs

Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

EXHIBIT 99.1 Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 09, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that managemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip

PROF / Profound Medical Corp. / DASEKE DON R - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Profound Medical Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 74319B502 (CUSIP Number) March 7, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip

Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of United States Code, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 99.5 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 40-F of Profound Medical Corp. (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company cert

Certifications required by Rule 13a-14(a) or Rule 15d-14(a), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 99.4 CERTIFICATION I, Arun Menawat, certify that: 1. I have reviewed this annual report on Form 40-F of Profound Medical Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect

the annual information form of the Corporation for the year ended December 31, 2023 dated March 7, 2024 (the “

Table of Contents Exhibit 99.1 PROFOUND MEDICAL CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2023 March 7, 2024 Table of Contents TABLE OF CONTENTS Page SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 2 TRADEMARKS AND TRADE NAMES 2 GLOSSARY 2 ITEM 1. CORPORATE STRUCTURE 5 ITEM 2. GENERAL DEVELOPMENT OF THE BUSINESS 7 ITEM 3. NARRATIVE DESCRIPTION OF TH

Consolidated Financial Statements of the Company for its fiscal year ended December 31, 2023

Exhibit 99.3 PROFOUND MEDICAL CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 PRESENTED IN US DOLLARS (000s) Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Profound Medical Corp. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Profound Medical Corp. and

The management’s discussion and analysis of financial condition and results of operations of the Registrant for the financial years ended December 31, 2023 and December 2022 (incorporated by reference to Exhibit 99.2 to the Annual Report Form 40-F, filed on March 7, 2024).

Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS DECEMBER 31, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the years ended December 31, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of March 7, 2024 should be read in conjunction with the December 31, 2023 audited co

Consent of Independent Registered Public Accounting Firm

Exhibit 99.6 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in this Annual Report on Form 40-F for the year ended December 31, 2023 of Profound Medical Corp. of our report dated March 7, 2024, relating to the consolidated financial statements which appears in Exhibit 99.3 incorporated by reference in this Annual Report on Form 40-F. We

United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F

United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission File Number 001-39032 Profound Medical Corp. (Exact name of Registrant as specified

Profound Medical Corp.’s Clawback Policy

Exhibit 97 PROFOUND MEDICAL CORP. CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Profound Medical Corp. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefo

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results TORONTO, March 07, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the four

Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference

EXHIBIT 99.1 Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference TORONTO, March 04, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3903

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

EXHIBIT 99.1 Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will a

PROF / Profound Medical Corp. / GAGNON SECURITIES LLC - SC 13G/A Passive Investment

SC 13G/A 1 profound13ga6.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

PROF / Profound Medical Corp. / LETKO, BROSSEAU & ASSOCIATES INC Passive Investment

SC 13G/A 1 profdmed1223.txt SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No One) PROFOUND MEDICAL CORP. .............. (Name of Issuer) COMMON SHARES ....................................................................... (Title of Class of Securities) 74319B502 ...................................

PROF / Profound Medical Corp. / FIL Ltd Passive Investment

SCHEDULE 13G Amendment No. 4 PROFOUND MEDICAL CORP COMMON STOCK Cusip #74319B502 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #74319B502 Item 1: Reporting Person - FIL Limited Item 2: (a) [ ] (b) [ ] Item 4: Bermuda Item 5: 1,200,635 Item 6: 0 Item 7: 1,200,635 Item 8: 0 Item 9: 1,200,635 Item

Profound Medical Announces Non-Brokered Private Placement

EXHIBIT 99.1 Profound Medical Announces Non-Brokered Private Placement TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

PROF / Profound Medical Corp. / DASEKE DON R - THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Profound Medical Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 74319B502 (CUSIP Number) January 10, 202

Joint Filing Agreement

EX-99.1 2 ex991to13g14015prof12212023.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statements on Schedule 13G with respect to the Common Shares, no par value, of Profound Medical Corp., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues

EXHIBIT 99.1 Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaud

FORM 51-102F3 MATERIAL CHANGE REPORT

Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change December 27, 2023 3. News Release Press releases relating to the material change were disseminated via Globe Newswire on December 27, 2023 and were subsequently filed on SEDAR+. 4. S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of

Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares

Exhibit 99.1 Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares TORONTO, ON (December 27, 2023) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the public of US$7.50 per C

PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022

TABLE OF CONTENTS  FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10   FILE NO. 333-263248 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated March 23, 2022 to which it relates, as amended or supplemented, and each document incorporate

2,666,667 COMMON SHARES PROFOUND MEDICAL CORP. UNDERWRITING AGREEMENT

Exhibit 99.1 2,666,667 COMMON SHARES PROFOUND MEDICAL CORP. UNDERWRITING AGREEMENT December 27, 2023 Titan Partners Group LLC, a division of American Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of

Profound Medical Announces Proposed Public Offering of Common Shares

EXHIBIT 99.1 Profound Medical Announces Proposed Public Offering of Common Shares TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company inten

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of

Profound Medical Announces Proposed Public Offering of Common Shares

Exhibit 99.1 Profound Medical Announces Proposed Public Offering of Common Shares TORONTO, ON (December 27, 2023) - Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company intends to f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

PRELIMINARY PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022

TABLE OF CONTENTS  FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10   FILE NO. 333-263248 SUBJECT TO COMPLETION, DATED DECEMBER 27, 2023 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commissi

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

EXHIBIT 99.1 Profound Medical to Participate in the Stifel 2023 Healthcare Conference TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an upda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting

EXHIBIT 99.1 Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, pursuant to the 2

PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s)

Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and nine months ended September 30, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of November 2, 2023 should be read in conjunction with the Septemb

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2023. 2. No misrepresentations: Based

PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s)

Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, 2023 $ December 31, 2022 $ Assets Current assets Cash 33,625 46,517 Trade and other receivables (note 3) 6,619 6,344 Inventory (note 4) 7,425 7,941 Prepa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin

FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE

Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2023. 2. No misrepresentations: Based on

Profound Medical Announces Third Quarter 2023 Financial Results

EXHIBIT 99.1 Profound Medical Announces Third Quarter 2023 Financial Results TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow

EXHIBIT 99.1 Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its

Profound Medical 2023 Virtual Analyst & Investor Day Agenda

EXHIBIT 99.1 Profound Medical 2023 Virtual Analyst & Investor Day Agenda TORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Invest

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule

EXHIBIT 99.1 Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cust

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13

EXHIBIT 99.1 Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13 TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst & Investor Day eve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference

EXHIBIT 99.1 Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present

PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022

TABLE OF CONTENTS  FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10  FILE NO. 333-263248 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated March 23, 2022 to which it relates, as amended or supplemented, and each document incorporated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

Profound Medical Announces At-the-Market Offering of up to US$30,000,000

EXHIBIT 99.1 Profound Medical Announces At-the-Market Offering of up to US$30,000,000 TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) announces that it has established an at-the-market equity program (the “ATM Program”) that allows the Company, through certain securities dealers acting as agents (together, the “Agents“), to i

PROFOUND MEDICAL CORP. Up to US$30,000,000 of Common Shares Equity Distribution Agreement

Exhibit 99.2 PROFOUND MEDICAL CORP. Up to US$30,000,000 of Common Shares Equity Distribution Agreement September 6, 2023 Stifel Nicolaus Canada Inc. 161 Bay Street, Suite 3800 Toronto, ON M5J 2S1 Stifel, Nicolaus & Company, Incorporated One South Street 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Profound Medical Corp., a corporation organized under the laws of the Province of Ontar